Literature DB >> 23330071

Molecular mechanisms of triggering, amplifying and targeting RANK signaling in osteoclasts.

Yukiko Kuroda1, Koichi Matsuo.   

Abstract

Osteoclast differentiation depends on receptor activator of nuclear factor-κB (RANK) signaling, which can be divided into triggering, amplifying and targeting phases based on how active the master regulator nuclear factor of activated T-cells cytoplasmic 1 (NFATc1) is. The triggering phase is characterized by immediate-early RANK signaling induced by RANK ligand (RANKL) stimulation mediated by three adaptor proteins, tumor necrosis factor receptor-associated factor 6, Grb-2-associated binder-2 and phospholipase C (PLC)γ2, leading to activation of IκB kinase, mitogen-activated protein kinases and the transcription factors nuclear factor (NF)-κB and activator protein-1 (AP-1). Mice lacking NF-κB p50/p52 or the AP-1 subunit c-Fos (encoded by Fos) exhibit severe osteopetrosis due to a differentiation block in the osteoclast lineage. The amplification phase occurs about 24 h later in a RANKL-induced osteoclastogenic culture when Ca(2+) oscillation starts and the transcription factor NFATc1 is abundantly produced. In addition to Ca(2+) oscillation-dependent nuclear translocation and transcriptional auto-induction of NFATc1, a Ca(2+) oscillation-independent, osteoblast-dependent mechanism stabilizes NFATc1 protein in differentiating osteoclasts. Osteoclast precursors lacking PLCγ2, inositol-1,4,5-trisphosphate receptors, regulator of G-protein signaling 10, or NFATc1 show an impaired transition from the triggering to amplifying phases. The final targeting phase is mediated by activation of numerous NFATc1 target genes responsible for cell-cell fusion and regulation of bone-resorptive function. This review focuses on molecular mechanisms for each of the three phases of RANK signaling during osteoclast differentiation.

Entities:  

Keywords:  Ca2+ oscillation; Immunoreceptor tyrosine-based activation motif; Nuclear factor of activated T-cells cytoplasmic 1; Receptor activator of nuclear factor-κB ligand; Tumor necrosis factor receptor-associated factor 6; c-Fos

Year:  2012        PMID: 23330071      PMCID: PMC3547110          DOI: 10.5312/wjo.v3.i11.167

Source DB:  PubMed          Journal:  World J Orthop        ISSN: 2218-5836


  77 in total

1.  Structural and functional insights of RANKL-RANK interaction and signaling.

Authors:  Changzhen Liu; Thomas S Walter; Peng Huang; Shiqian Zhang; Xuekai Zhu; Ying Wu; Lucy R Wedderburn; Peifu Tang; Raymond J Owens; David I Stuart; Jingshan Ren; Bin Gao
Journal:  J Immunol       Date:  2010-05-14       Impact factor: 5.422

2.  RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis.

Authors:  Jin Gohda; Toru Akiyama; Takako Koga; Hiroshi Takayanagi; Sakae Tanaka; Jun-ichiro Inoue
Journal:  EMBO J       Date:  2005-01-27       Impact factor: 11.598

3.  Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals.

Authors:  Masahiro Shinohara; Takako Koga; Kazuo Okamoto; Shinya Sakaguchi; Kimiko Arai; Hisataka Yasuda; Toshiyuki Takai; Tatsuhiko Kodama; Tomohiro Morio; Raif S Geha; Daisuke Kitamura; Tomohiro Kurosaki; Wilfried Ellmeier; Hiroshi Takayanagi
Journal:  Cell       Date:  2008-03-07       Impact factor: 41.582

Review 4.  Transcriptional regulation by calcium, calcineurin, and NFAT.

Authors:  Patrick G Hogan; Lin Chen; Julie Nardone; Anjana Rao
Journal:  Genes Dev       Date:  2003-09-15       Impact factor: 11.361

5.  Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation.

Authors:  Insun Song; Jung Ha Kim; Kabsun Kim; Hye Mi Jin; Bang Ung Youn; Nacksung Kim
Journal:  FEBS Lett       Date:  2009-07-02       Impact factor: 4.124

6.  Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis.

Authors:  Takako Koga; Masanori Inui; Kazuya Inoue; Sunhwa Kim; Ayako Suematsu; Eiji Kobayashi; Toshio Iwata; Hiroshi Ohnishi; Takashi Matozaki; Tatsuhiko Kodama; Tadatsugu Taniguchi; Hiroshi Takayanagi; Toshiyuki Takai
Journal:  Nature       Date:  2004-04-15       Impact factor: 49.962

7.  Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation.

Authors:  Fumiyo Ikeda; Riko Nishimura; Takuma Matsubara; Sakae Tanaka; Jun-ichiro Inoue; Sakamuri V Reddy; Kenji Hata; Kenji Yamashita; Toru Hiraga; Toshiyuki Watanabe; Toshio Kukita; Katsuji Yoshioka; Anjana Rao; Toshiyuki Yoneda
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

8.  Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis.

Authors:  Baohong Zhao; Masamichi Takami; Atsushi Yamada; Xiaogu Wang; Takako Koga; Xiaoyu Hu; Tomohiko Tamura; Keiko Ozato; Yongwon Choi; Lionel B Ivashkiv; Hiroshi Takayanagi; Ryutaro Kamijo
Journal:  Nat Med       Date:  2009-08-30       Impact factor: 53.440

9.  Autoamplification of NFATc1 expression determines its essential role in bone homeostasis.

Authors:  Masataka Asagiri; Kojiro Sato; Takako Usami; Sae Ochi; Hiroshi Nishina; Hiroki Yoshida; Ikuo Morita; Erwin F Wagner; Tak W Mak; Edgar Serfling; Hiroshi Takayanagi
Journal:  J Exp Med       Date:  2005-11-07       Impact factor: 14.307

10.  Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL.

Authors:  Cristina Sobacchi; Annalisa Frattini; Matteo M Guerrini; Mario Abinun; Alessandra Pangrazio; Lucia Susani; Robbert Bredius; Grazia Mancini; Andrew Cant; Nick Bishop; Peter Grabowski; Andrea Del Fattore; Chiara Messina; Gabriella Errigo; Fraser P Coxon; Debbie I Scott; Anna Teti; Michael J Rogers; Paolo Vezzoni; Anna Villa; Miep H Helfrich
Journal:  Nat Genet       Date:  2007-07-15       Impact factor: 38.330

View more
  14 in total

1.  RANKL-RANK interaction in immune regulatory systems.

Authors:  Taishin Akiyama; Miho Shinzawa; Nobuko Akiyama
Journal:  World J Orthop       Date:  2012-09-18

2.  Nur77 prevents excessive osteoclastogenesis by inducing ubiquitin ligase Cbl-b to mediate NFATc1 self-limitation.

Authors:  Xiaoxiao Li; Wei Wei; HoangDinh Huynh; Hao Zuo; Xueqian Wang; Yihong Wan
Journal:  Elife       Date:  2015-07-14       Impact factor: 8.140

3.  Vitamin D endocrine system and osteoclasts.

Authors:  Naoyuki Takahashi; Nobuyuki Udagawa; Naoyuki Udagawa; Tatsuo Suda
Journal:  Bonekey Rep       Date:  2014-02-05

4.  Noncanonical G-protein-dependent modulation of osteoclast differentiation and bone resorption mediated by Pasteurella multocida toxin.

Authors:  Julia Strack; Hannah Heni; Ralf Gilsbach; Lutz Hein; Klaus Aktories; Joachim H C Orth
Journal:  MBio       Date:  2014-11-11       Impact factor: 7.867

5.  N-acetylglucosamine suppresses osteoclastogenesis in part through the promotion of O-GlcNAcylation.

Authors:  Tomoharu Takeuchi; Moyuko Nagasaka; Miyuki Shimizu; Mayumi Tamura; Yoichiro Arata
Journal:  Bone Rep       Date:  2016-02-03

6.  The Influence of DNA Methylation on Bone Cells.

Authors:  Sjur Reppe; Harish Datta; Kaare M Gautvik
Journal:  Curr Genomics       Date:  2015-12       Impact factor: 2.236

7.  Osteoprotegerin Regulates Pancreatic β-Cell Homeostasis upon Microbial Invasion.

Authors:  Yukiko Kuroda; Kenta Maruyama; Hideki Fujii; Isamu Sugawara; Shigeru B H Ko; Hisataka Yasuda; Hidenori Matsui; Koichi Matsuo
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

8.  Conditional deletion of CD98hc inhibits osteoclast development.

Authors:  Hideki Tsumura; Morihiro Ito; Masamichi Takami; Miyuki Arai; Xiao-Kang Li; Toshio Hamatani; Arisa Igarashi; Shuji Takada; Kenji Miyado; Akihiro Umezawa; Yasuhiko Ito
Journal:  Biochem Biophys Rep       Date:  2015-12-02

9.  Dectin-1 signaling inhibits osteoclastogenesis via IL-33-induced inhibition of NFATc1.

Authors:  Xiaoqing Zhu; Yinghua Zhao; Yuxue Jiang; Tianxue Qin; Jintong Chen; Xiao Chu; Qing Yi; Sujun Gao; Siqing Wang
Journal:  Oncotarget       Date:  2017-06-08

10.  mTORC1 impedes osteoclast differentiation via calcineurin and NFATc1.

Authors:  HoangDinh Huynh; Yihong Wan
Journal:  Commun Biol       Date:  2018-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.